Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

Jun 16, 2025 - 17:40
 0
Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.